Výsledky vyhledávání - "R. Frederich"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

WCN23-0356 HYPOGLYCEMIA AND KIDNEY EVENTS IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL

Autor: D. Cherney, F. Cosentino, R. E. Pratley, S. Dagogo-Jack, D.K. McGuire, M. Maldonado, R. Frederich, W. Fu

Publikováno v: Kidney International Reports. 8:S191-S192

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e029b3d83903556737851bdfe32d53f
https://doi.org/10.1016/j.ekir.2023.02.426

Zobrazit plný text záznamu

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Autor: A Pandey, A A Kolkailah, F Cosentino, C P Cannon, R Frederich, D Z I Cherney, S Dagogo-Jack, R E Pratley, N B Cater, I Gantz, J P Mancuso, D K McGuire

Publikováno v: European Heart Journal. 43

Introduction There is controversy over whether SGLT2 inhibitors have efficacy in high-risk patients with heart failure (HF) and ejection fraction (EF) >60% with or without type 2 diabetes (T2D). The VERTIS CV trial studied a population of patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf7752a457084631c712696b851cf994
https://doi.org/10.1093/eurheartj/ehac544.962

Zobrazit plný text záznamu

Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial

Autor: B.S. Wojeck, S.E. Inzucchi, I.J. Neeland, J.P. Mancuso, R. Frederich, U. Masiukiewicz, N.B. Cater, D.K. McGuire, C.P. Cannon, H.K. Yaggi

Publikováno v: Sleep Medicine. 100:S249-S250

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0740793738d625dcd67f9061eeba9f4a
https://doi.org/10.1016/j.sleep.2022.05.671

Zobrazit plný text záznamu

IDF2022-0796 Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV

Autor: F. Cosentino, S. Dagogo-Jack, R. Frederich, C.P. Cannon, D.Z.I. Cherney, J.P. Mancuso, W. Wynant, J. Liu, N.B. Cater, R.E. Pratley

Publikováno v: Diabetes Research and Clinical Practice. 197:110329

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7ef9e5f701748b8ded73368c581e557
https://doi.org/10.1016/j.diabres.2023.110329

Zobrazit plný text záznamu

Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

Autor: F Cosentino, C P Cannon, D Z I Cherney, S Dagogo-Jack, R E Pratley, B Charbonnel, W J Shih, J P Mancuso, M Maldonado, R Frederich, N B Cater, S Wang, D K McGuire

Publikováno v: European Heart Journal. 42

Introduction We analysed data from the VERTIS CV trial that investigated the CV and kidney safety and efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (ERTU) vs placebo (PBO) to assess the impact of metformin (MET) use a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40546bdf2d98a520b0d92f68efc6f34b
https://doi.org/10.1093/eurheartj/ehab724.2650

Zobrazit plný text záznamu

Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

Autor: M W Segar, A Pandey, D Z I Cherney, C P Cannon, F Cosentino, S Dagogo-Jack, R E Pratley, W J Shih, R Frederich, N B Cater, M Maldonado, J Liu, C Liu, A Pong, D K McGuire

Publikováno v: European Heart Journal. 42

Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce risk of hospitalisation for heart failure (HHF) in outcome trials, but the biological mediators underlying the therapeutic benefit are not well established. Purpose To identify pot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::238e0337f093b1e9c38f0d650c770887
https://doi.org/10.1093/eurheartj/ehab724.2649

Zobrazit plný text záznamu

POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV

Autor: M. Maldonado, A. Pong, Jie Liu, W.J. Shih, Christopher P. Cannon, Richard E. Pratley, R. Frederich, Samuel Dagogo-Jack, David Z.I. Cherney, Darren K. McGuire, Francesco Cosentino, B. Charbonnel, Chih-Chin Liu

Publikováno v: Kidney International Reports, Vol 6, Iss 4, Pp S154-S155 (2021)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffabe9ee5e2829e736746394112bbd09
http://www.sciencedirect.com/science/article/pii/S2468024921005179

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání